



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
G01N 33/574 ^(2006.01)

(86) International application number:
PCT/US2011/034005

(48) Corrigendum issued on:
02.10.2019 Bulletin 2019/40

(87) International publication number:
WO 2011/139721 (10.11.2011 Gazette 2011/45)

(45) Date of publication and mention
of the grant of the patent:
09.01.2019 Bulletin 2019/02

(21) Application number: **11721599.6**

(22) Date of filing: **26.04.2011**

(54) **CANCER BIOMARKERS AND METHODS OF USE THEREOF**

KREBSBIOMARKER UND ANWENDUNGSVERFAHREN DAFÜR

BIOMARQUEURS DE CANCER ET LEURS PROCÉDÉS D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **27.04.2010 US 328565 P**

(43) Date of publication of application:
06.03.2013 Bulletin 2013/10

(60) Divisional application:
18209239.5 / 3 508 854

(73) Proprietors:
• **The Regents of the University of California**
Oakland, CA 94607 (US)
• **Yale University**
New Haven, CT 06510 (US)
• **Prelude Corporation**
Laguna Hills, CA 92653 (US)

(72) Inventors:
• **KERLIKOWSKE, Karla**
San Anselmo, CA 94960 (US)
• **TLSTY, Thea, D.**
San Francisco, CA 94116 (US)

• **GAUTHIER, Mona, L.**
Toronto, Ontario M8V 1N3 (CA)
• **BERMAN, Hal, K.**
Toronto, Ontario M5G 2C1 (CA)
• **BREMER, Troy**
Irvine, CA 92604 (US)
• **MOLINARO, Annette, M.**
New Haven, CT 06511 (US)

(74) Representative: **Zacco Sweden AB**
P.O. Box 5581
114 85 Stockholm (SE)

(56) References cited:
WO-A2-2008/008284

• **MYLONAS IOANNIS ET AL: "Expression of**
Her2/neu, steroid receptors (ER and PR), Ki67 and
p53 in inv'asive mammary ductal carcinoma
associated with ductal carcinoma in situ (DCIS)
versus invasive breast cancer alone",
ANTICANCER RESEARCH, vol. 25, no. 3A, May
2005 (2005-05), pages 1719-1723,
XP000002657066, ISSN: 0250-7005

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- GAUTHIER MONA L ET AL: "Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors", CANCER CELL, vol. 12, no. 5, November 2007 (2007-11), pages 479-491, XP000002657067, ISSN: 1535-6108
- FARATIAN D ET AL: "Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma", HISTOPATHOLOGY 200901 GB LNKD- DOI:10.1111/J.1365-2559.2008.03191.X, vol. 54, no. 2, January 2009 (2009-01), pages 254-257, XP009151332, ISSN: 0309-0167
- VAN DER GROEP P ET AL: "Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers", JOURNAL OF CLINICAL PATHOLOGY 2009 BMJ PUBLISHING GROUP GBR LNKD- DOI:10.1136/JCP.2009.065524, vol. 62, no. 10, October 2009 (2009-10), pages 926-930, XP009151342, ISSN: 0021-9746
- PERRONE G ET AL: "COX-2 expression in DCIS: Correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features", HISTOPATHOLOGY 200505 GB LNKD- DOI:10.1111/J.1365-2559.2005.02132.X, vol. 46, no. 5, May 2005 (2005-05), pages 561-568, XP000002657070, ISSN: 0309-0167
- SCHORR M C ET AL: "Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?", APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY 2010 LIPPINCOTT WILLIAMS AND WILKINS USA LNKD- DOI:10.1097/PAI.0B013E3181ACADED, vol. 18, no. 1, January 2010 (2010-01), pages 51-54, XP009151326, ISSN: 1541-2016